OncoSpherix, Inc. is pleased to announce that Kendyle Woodard, MBA, is serving as Chief Operating Officer for the company. Ms. Woodard is a business operations executive with 20+ years of experience in management, marketing and business development supporting startups, non-profits, manufacturers, and consulting companies. Margaret K. Offermann, M.D., Ph.D., President and CEO of OncoSpherix, remarked, “We are thrilled to have Kendyle as a part of OncoSpherix’s growing team. Her corporate operations experience taking a bioscience company from startup to publicly listed on Nasdaq will be valuable as we advance our dual HIF inhibitors for the treatment of advanced cancers in the clinic and embark on our Series A funding round.”

Ms. Woodard was co-founder, Executive Vice President and Corporate Secretary of Innovate Biopharmaceuticals, a public GI-focused drug development company with a first-in-class Phase 3 treatment for celiac disease, where she helped raise $30+MM and managed the company’s operations. She will manage the company’s business operations. Ms. Woodard earned her Bachelor of Science degree, magna cum laude, in international business and marketing from University of South Alabama, her Master of Business Administration degree, cum laude, focused on Innovation Management, from North Carolina State University, and is a graduate of Harvard Business School’s Executive Education, Women on Boards: Succeeding as a Corporate Director. Ms. Woodard is currently a member of BIO’s Tech Transfer Committee, SouthEast LifeSciences’ Planning Committee and Women Executives on Boards.